Get the Stockscreener App
7.12
1.86%
0.13
Adlai Nortye Ltd Adr stock is traded at $7.12, with a volume of 147.03K.
It is up +1.86% in the last 24 hours and down -26.67% over the past month.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
See More
Previous Close:
$6.99
Open:
$6.98
24h Volume:
147.03K
Relative Volume:
0.17
Market Cap:
$418.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-7.857
EPS:
-0.9062
Net Cash Flow:
-
1W Performance:
-3.91%
1M Performance:
-26.67%
6M Performance:
+300.00%
1Y Performance:
+217.86%
1-Day Range:
$6.92
$7.55
1-Week Range:
$6.56
$7.80
52-Week Range:
$0.8786
$12.09
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
7.12 | 410.60M | 0 | 0 | 0 | -0.9062 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Leerink Partners | Outperform |
| Feb-13-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye Ltd. sponsored ADR (ANL) upgraded to buy: Here's why - MSN
Adlai Nortye Ltd. Sponsored ADR (ANL) Raised to Buy: The Reason Behind This Change - Bitget
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance
ETFs Investing in Adlai Nortye Ltd. Sponsored ADR Stocks - TradingView
Adlai Nortye (NASDAQ: ANL) files $600M shelf; 21.5M ADSs resale - Stock Titan
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic - TipRanks
H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target - Investing.com South Africa
Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025 - TipRanks
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire Inc.
Short Interest in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Rises By 458.7% - MarketBeat
Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline - The Globe and Mail
Adlai Nortye raises $140 million in private placement By Investing.com - Investing.com South Africa
Adlai Nortye prices 64.6M shares at $2.17 in private placement - TipRanks
Adlai Nortye raises $140 million in private placement - Investing.com
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World
AIFU Inc. – Sponsored ADR (NASDAQ:AIFU) Short Interest Update - Defense World
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% By Investing.com - Investing.com India
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating - Investing.com India
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating By Investing.com - Investing.com South Africa
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), UnitedHealth (UNH) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Short Interest in Global X Social Media ETF (NASDAQ:SOCL) Increases By 7,184.3% - Defense World
TerraVest Industries (TSE:TVK) Price Target Raised to C$209.00 at Canaccord Genuity Group - Defense World
Paycom Software (NYSE:PAYC) Price Target Cut to $185.00 by Analysts at Barclays - Defense World
Teledyne Technologies (NYSE:TDY) Given New $579.00 Price Target at Barclays - Defense World
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 6,821.4% in December - MarketBeat
Adlai Nortye narrows first-half 2025 loss as oncology pipeline advances - MSN
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xoma (XOMA) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd ADR (ANL-Q) Stock Price and News - The Globe and Mail
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm - Investing.com India
Adlai Nortye Narrows First-Half 2025 Loss as Oncology Pipeline Advances - TipRanks
Adlai Nortye Licenses Pan-RAS Inhibitor AN9025 to ASK Pharm for Greater China - TipRanks
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal - Investing.com
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - Sahm
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):